A comparative lack of diversity in their offerings could pose higher earnings pressure to the ‘pure’ pharma players such as AstraZeneca (NYSE:AZN), Bristol-Myers (NYSE:BMY) and Eli Lilly (NYSE:LLY), over the next three years, reports Fitch, while firms that are more diversified, like Johnson & Johnson (NYSE:JNJ) and Bayer (BAYRY.PK), will be better situated in that regard. It’s further noted that the former group, who have plenty of shopping capital but relatively scant pipelines, might be lured into solving the problem by looking at acquisitions.
Shares of the Irish drug producer Warner Chilcott (NASDAQ:WCRX) pop following confirmation that the firm is in preliminary talks with possible suitors, “to explore a broad range of strategic alternatives to enhance shareholder value.”
Biogen (NASDAQ:BIIB) shares rise after Deutsche Bank reveals that it conducted a survey and found that between 40 and 57 percent of patients who currently take Baxter’s (NYSE:BAX) Advate, might switch to the former’s new hemophilia treatment if given a better price.
Accretive Health (NYSE:AH) fights back to recent accusations by the attorney general of Minnesota, calling for a dismissal of the claims, which it brands as distorted, “factually baseless,” and “legally indefensible”.
Celgene (NASDAQ:CELG) shares are said by UBS to be a buying opportunity, following the company’s first quarter figures that disappointed investors. UBS, who maintains a Buy, says that the numbers are from transient problems, and that Celgene remains on track for the second quarter.
Earnings Report: NuVasive Inc. Earnings: Margins Shrink Again, Net Income Falls.